Articles


FDA approves first complete long-acting HIV-1 treatment


ViiV Healthcare’s Cabenuva will be available in the U.S. in February

FDA okayed the first drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen positive lesions in men with prostate cancer.

First prostate cancer imaging drug approved

The drug is the first FDA-approved therapy for these rare genetic diseases.

FDA clears treatment for rare obesity diseases

Recalls of metformin products due to higher levels of the probable carcinogenic ingredient N-Nitrosodimethylamine (NDMA) than allowed continue.

Metformin recalls continue

The combination therapy of Opdivo plus Yervoy will treat the cancer caused by inhaling asbestos fibers.



FDA clears first treatment for mesothelioma in 16 years

Both recalls are due to sub-potency of drugs that treat hypothyroidism.

Major thyroid med recall underway

The drug’s indication for marginal zone lymphoma (MZL) may not be approved until February 2021.


Investigational lymphoma treatment gets FDA nod

Five other manufacturers have recalled the popular diabetes medication due to the presence of a the carcinogenic ingredient.


Another pharma maker recalls metformin over NDMA

Gilead will present new data on virologic suppression in adults 65 years and older at AIDS 2020: Virtual this week.

Popular HIV-1 med successful, particularly in order adults

Investigational treatment will target marginal zone lymphoma (MZL) and follicular lymphoma (FL). 